Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

Carlos Castaneda, Kellen L. Meadows, Roxanne Truax, Michael A. Morse, Scott H Kaufmann, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Herbert I. Hurwitz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. Methods: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Doselimiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336-induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. Results: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. Conclusion The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume67
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Pharmacokinetics
Tumors
Appointments and Schedules
Toxicity
Neoplasms
Maximum Tolerated Dose
Transferases
Lamins
Prenylation
Mouth Mucosa
Anorexia
Bioactivity
Pharmaceutical Preparations
Nausea
Fatigue
lonafarnib
Diarrhea
Blood
Parents
Urine

Keywords

  • Advanced solid tumors
  • Lonafarnib
  • Pharmacokinetics
  • Phase I
  • SCH 66336

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. / Castaneda, Carlos; Meadows, Kellen L.; Truax, Roxanne; Morse, Michael A.; Kaufmann, Scott H; Petros, William P.; Zhu, Yali; Statkevich, Paul; Cutler, David L.; Hurwitz, Herbert I.

In: Cancer Chemotherapy and Pharmacology, Vol. 67, No. 2, 02.2011, p. 455-463.

Research output: Contribution to journalArticle

Castaneda, Carlos ; Meadows, Kellen L. ; Truax, Roxanne ; Morse, Michael A. ; Kaufmann, Scott H ; Petros, William P. ; Zhu, Yali ; Statkevich, Paul ; Cutler, David L. ; Hurwitz, Herbert I. / Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 67, No. 2. pp. 455-463.
@article{756177e2e38541469c9572c38274f9c4,
title = "Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors",
abstract = "Purpose: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. Methods: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Doselimiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336-induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. Results: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. Conclusion The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.",
keywords = "Advanced solid tumors, Lonafarnib, Pharmacokinetics, Phase I, SCH 66336",
author = "Carlos Castaneda and Meadows, {Kellen L.} and Roxanne Truax and Morse, {Michael A.} and Kaufmann, {Scott H} and Petros, {William P.} and Yali Zhu and Paul Statkevich and Cutler, {David L.} and Hurwitz, {Herbert I.}",
year = "2011",
month = "2",
doi = "10.1007/s00280-010-1488-5",
language = "English (US)",
volume = "67",
pages = "455--463",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

AU - Castaneda, Carlos

AU - Meadows, Kellen L.

AU - Truax, Roxanne

AU - Morse, Michael A.

AU - Kaufmann, Scott H

AU - Petros, William P.

AU - Zhu, Yali

AU - Statkevich, Paul

AU - Cutler, David L.

AU - Hurwitz, Herbert I.

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. Methods: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Doselimiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336-induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. Results: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. Conclusion The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.

AB - Purpose: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. Methods: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Doselimiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336-induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. Results: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. Conclusion The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.

KW - Advanced solid tumors

KW - Lonafarnib

KW - Pharmacokinetics

KW - Phase I

KW - SCH 66336

UR - http://www.scopus.com/inward/record.url?scp=79953791317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953791317&partnerID=8YFLogxK

U2 - 10.1007/s00280-010-1488-5

DO - 10.1007/s00280-010-1488-5

M3 - Article

VL - 67

SP - 455

EP - 463

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -